ADCT
What one share of ADC Therapeutics SA holds
Pharmaceutical Preparations
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.
ADC Therapeutics SA’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.53 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.69 |
| Cash and investments | $1.72 |
| Book value | −$1.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $2.69 | −$2.01 | $0.01 | −$1.78 | — | $0.99 |
| 2023 | $0.85 | −$2.94 | $0.04 | −$1.49 | — | −$1.80 |
| 2024 | $0.73 | −$1.62 | $0.01 | −$1.28 | — | −$2.05 |
| 2025 | $0.64 | −$1.12 | $0.00 | −$1.11 | — | −$1.48 |